News

Sagent Pharmaceuticals has launched ondansetron in 5% dextrose injection in premix bags. Its an antiemetic and selective 5-HT3 receptor antagonist used to prevent nausea and vomiting caused by

The US and European patent authorities have granted seven additional patents to Gen-Probe. It extend the company’s intellectual property estate related to automated instrument systems for nucleic acid

Boehringer Ingelheim is going to initiate phase III clinical study of BIBW 2992 (Tovok), as first-line treatment in non-small cell lung cancer (NSCLC) patients with epidermal growth factor

Micronics has been awarded a Small Business Technology Transfer grant totaling approximately $440,000, to develop a rapid method for nucleic acid detection of known and emerging respiratory infections.

Law firm, Glancy Binkow & Goldberg has filed a lawsuit in the US District Court of Massachusetts, seeking a class action status on behalf of a class consisting

MannKind reported a net loss for the second quarter of 2009 of $55.6 million, or $0.54 per share, compared to a net loss of $79.8 million, or $0.79

SuperGen has reported preliminary results from phase Ib data of MP-470, tyrosine kinase and RAD51 suppressor. The results demonstrated an overall clinical benefit rate of 54%, when the

Arkema has posted sales figures of E1.16 billion, as compared to E1.5 billion in the second quarter of 2008, a decline of 22.7%. EBITDA stood at E70 million,

Shin Nippon Biomedical Laboratories (SNBL) is developing an intranasal form of the antiemetic drug, granisetron (TRG) in the US. SNBL has announced the first report on the results